J.P. Morgan analyst Tycho Peterson maintained a Buy rating on Guardant Health (GH – Research Report) on February 24 and set a price target of $150.00. The company’s shares closed last Friday at $57.92, close to its 52-week low of $56.81.
According to TipRanks.com, Peterson is a 5-star analyst with an average return of 11.0% and a 58.1% success rate. Peterson covers the Healthcare sector, focusing on stocks such as Singular Genomics Systems, Orasure Technologies, and Pacific Biosciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Guardant Health with a $123.56 average price target, implying a 104.8% upside from current levels. In a report issued on February 24, Wells Fargo also maintained a Buy rating on the stock with a $115.00 price target.
Guardant Health’s market cap is currently $6.17B and has a P/E ratio of -14.46.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Guardant Health, Inc. is a precision oncology company, which engages in provision of precision oncology testing and development services. It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood City, CA.
Read More on GH:
- J.P. Morgan Believes Diamondback (FANG) Still Has Room to Grow
- Krispy Kreme (DNUT) Gets a Buy Rating from J.P. Morgan
- J.P. Morgan Keeps a Buy Rating on Healthpeak Properties (PEAK)
- SITE Centers (SITC) Receives a Hold from J.P. Morgan
- J.P. Morgan Keeps Their Buy Rating on Kiniksa Pharmaceuticals (KNSA)